UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Design, synthesis and biological evaluation of novel scaffold benzo[4,5]imidazo [1,2-a]pyrazin-1-amine: Towards adenosine A2A receptor (A2A AR) antagonist

European journal of medicinal chemistry, 2021-01, Vol.210, p.113040, Article 113040

2021

Volltextzugriff (PDF)

The one-pot synthesis of butyl-1H-indol-3-alkylcarboxylic acid derivatives in ionic liquid as potent dual-acting agent for management of BPH

European journal of medicinal chemistry, 2020-11, Vol.205, p.112616-112616, Article 112616

2020

Volltextzugriff (PDF)

Recent Progress of Adenosine Receptor Modulators in the Development of Anticancer Chemotherapeutic Agents

Current pharmaceutical design, 2019-01, Vol.25 (26), p.2842-2858

2019

Volltextzugriff (PDF)

Advantageous safety profile of a dual selective alpha2C agonist/alpha2A antagonist antinociceptive agent

Fundamental & clinical pharmacology, 2014-08, Vol.28 (4), p.423-438

2014

Volltextzugriff (PDF)

Tamsulosin reduces nighttime urine production in benign prostatic hyperplasia patients with nocturnal polyuria: A prospective open-label long-term study using frequency-volume chart

Neurourology and urodynamics, 2012-01, Vol.31 (1), p.80-85

2012

Volltextzugriff (PDF)

A patent review of adenosine A2B receptor antagonists (2016-present)

Expert opinion on therapeutic patents, 2022-06, Vol.32 (6), p.689-712

2022

Volltextzugriff (PDF)

Androgen receptor: a potential therapeutic target for glioblastoma

Oncotarget, 2018-04, Vol.9 (28), p.19980-19993

2018

Volltextzugriff (PDF)

Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer

International journal of molecular sciences, 2021-10, Vol.22 (20), p.11088

2021

Volltextzugriff (PDF)

Alpha1-Adrenoceptor Antagonists Improve Bladder Storage Function Through Reduction of Afferent Activity in Rats With Bladder Outlet Obstruction

Neurourology and urodynamics, 2011-03, Vol.30 (3), p.461-467

2011

Volltextzugriff (PDF)

Discovery of Pyridone-Substituted Triazolopyrimidine Dual A2A/A1 AR Antagonists for the Treatment of Ischemic Stroke

ACS medicinal chemistry letters, 2022-03, Vol.13 (3), p.436-442

2022

Volltextzugriff (PDF)

Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator

Cell reports (Cambridge), 2018-12, Vol.25 (10), p.2808-2820.e4

2018

Volltextzugriff (PDF)

α2C-adrenoceptor modulators: a patent review

Expert opinion on therapeutic patents, 2011-04, Vol.21 (4), p.455-481

2011

Volltextzugriff (PDF)

Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications

Cells (Basel, Switzerland), 2020-12, Vol.9 (12), p.2653

2020

Volltextzugriff (PDF)

Consideration of breast cancer subtype in targeting the androgen receptor

Pharmacology & therapeutics (Oxford), 2019-08, Vol.200, p.135-147

2019

Volltextzugriff (PDF)

Overexpression of BQ323636.1 contributes to anastrozole resistance in AR+ve/ER+ve breast cancer

The Journal of pathology, 2023-10, Vol.261 (2), p.156-168

2023

Volltextzugriff (PDF)

Endocrine disrupting potential of selected azole and organophosphorus pesticide products through suppressing the dimerization of human androgen receptor in genomic pathway

Ecotoxicology and environmental safety, 2022-12, Vol.247, p.114246-114246, Article 114246

2022

Volltextzugriff (PDF)

Discovery of an enantiopure N-[2-hydroxy-3-phenyl piperazine propyl]-aromatic carboxamide derivative as highly selective α1D/1A-adrenoceptor antagonist and homology modelling

Chinese chemical letters, 2024-11, Vol.35 (11), p.109594, Article 109594

2024

Volltextzugriff (PDF)

Androgen Receptor, Although Not a Specific Marker For, Is a Novel Target to Suppress Glioma Stem Cells as a Therapeutic Strategy for Glioblastoma

Frontiers in oncology, 2021-05, Vol.11, p.616625-616625

2021

Volltextzugriff (PDF)

Maternal exposure to imazalil disrupts the endocrine system in F1 generation mice

Molecular and cellular endocrinology, 2019-04, Vol.486, p.105-112

2019

Volltextzugriff (PDF)

A2A Receptor Ligands: Past, Present and Future Trends

Current topics in medicinal chemistry, 2010-06, Vol.10 (9), p.902-922

2010

Volltextzugriff (PDF)

A Selective Adenosine A3 Receptor Antagonist, HL3501, Has Therapeutic Potential in Preclinical Liver and Renal Fibrosis Models

In vivo (Athens), 2022-09, Vol.36 (5), p.2186-2193

2022

Volltextzugriff (PDF)

Androgen Receptor Activation in Glioblastoma Can Be Achieved by Ligand-Independent Signaling through EGFR-A Potential Therapeutic Target

International journal of molecular sciences, 2021-10, Vol.22 (20), p.10954

2021

Volltextzugriff (PDF)

Computational studies of the binding modes of A₂A adenosine receptor antagonists

Amino acids, 2008-08, Vol.35 (2), p.389-396

2008

Volltextzugriff (PDF)

Phase I clinical trial of HC‐1119: A deuterated form of enzalutamide

International journal of cancer, 2021-10, Vol.149 (7), p.1473-1482

2021

Volltextzugriff (PDF)

Comparison of MLR, PLS and GA-MLR in QSAR analysis

SAR and QSAR in environmental research, 2003-10, Vol.14 (5-6), p.433-445

2003

Volltextzugriff (PDF)

1 – 25 von 369

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(341)
Mit Volltextzugriff
(320)

Publikationsform

Artikel
(359)
Buchkapitel
(10)

Sprache

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

Design, synthesis and biological evaluation of novel scaffold benzo[4,5]imidazo [1,2-a]pyrazin-1-amine: Towards adenosine A2A receptor (A2A AR) antagonist

The one-pot synthesis of butyl-1H-indol-3-alkylcarboxylic acid derivatives in ionic liquid as potent dual-acting agent for management of BPH

Recent Progress of Adenosine Receptor Modulators in the Development of Anticancer Chemotherapeutic Agents

Advantageous safety profile of a dual selective alpha2C agonist/alpha2A antagonist antinociceptive agent

Tamsulosin reduces nighttime urine production in benign prostatic hyperplasia patients with nocturnal polyuria: A prospective open-label long-term study using frequency-volume chart

A patent review of adenosine A2B receptor antagonists (2016-present)

Androgen receptor: a potential therapeutic target for glioblastoma

Role of PI3K-AKT-mTOR Pathway as a Pro-Survival Signaling and Resistance-Mediating Mechanism to Therapy of Prostate Cancer

Alpha1-Adrenoceptor Antagonists Improve Bladder Storage Function Through Reduction of Afferent Activity in Rats With Bladder Outlet Obstruction

Discovery of Pyridone-Substituted Triazolopyrimidine Dual A2A/A1 AR Antagonists for the Treatment of Ischemic Stroke

Polycomb- and Methylation-Independent Roles of EZH2 as a Transcription Activator

α2C-adrenoceptor modulators: a patent review

Androgen Receptor Signaling Pathway in Prostate Cancer: From Genetics to Clinical Applications

Consideration of breast cancer subtype in targeting the androgen receptor

Overexpression of BQ323636.1 contributes to anastrozole resistance in AR+ve/ER+ve breast cancer

Endocrine disrupting potential of selected azole and organophosphorus pesticide products through suppressing the dimerization of human androgen receptor in genomic pathway

Discovery of an enantiopure N-[2-hydroxy-3-phenyl piperazine propyl]-aromatic carboxamide derivative as highly selective α1D/1A-adrenoceptor antagonist and homology modelling

Androgen Receptor, Although Not a Specific Marker For, Is a Novel Target to Suppress Glioma Stem Cells as a Therapeutic Strategy for Glioblastoma

Maternal exposure to imazalil disrupts the endocrine system in F1 generation mice

A2A Receptor Ligands: Past, Present and Future Trends

A Selective Adenosine A3 Receptor Antagonist, HL3501, Has Therapeutic Potential in Preclinical Liver and Renal Fibrosis Models

Androgen Receptor Activation in Glioblastoma Can Be Achieved by Ligand-Independent Signaling through EGFR-A Potential Therapeutic Target

Computational studies of the binding modes of A₂A adenosine receptor antagonists

Phase I clinical trial of HC‐1119: A deuterated form of enzalutamide

Comparison of MLR, PLS and GA-MLR in QSAR analysis

Suchergebnisse filtern